<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18471">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105610</url>
  </required_header>
  <id_info>
    <org_study_id>VOLATILE/38/OSR</org_study_id>
    <nct_id>NCT02105610</nct_id>
  </id_info>
  <brief_title>Volatile Anesthetics to Reduce Mortality in Cardiac Surgery</brief_title>
  <official_title>Volatile Anesthetics to Reduce Mortality in Cardiac Surgery: A Multicentre Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Vita-Salute San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Vita-Salute San Raffaele</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is initial evidence that the choice of anesthesia can influence survival in the
      specific setting of coronary artery bypass grafting surgery (CABG).

      A recent international consensus conference included volatile agents among the few
      drugs/techniques/strategies that might reduce perioperative mortality in cardiac surgery and
      that should be further studied. Volatile anesthetics (desflurane, isoflurane and
      sevoflurane) have non-anesthetic pharmacological characteristics that confer cardiac
      protection when compared to Total IntraVenous Anesthesia (TIVA). Several randomized
      controlled studies were summarized in a meta-analysis that documented a reduction in
      perioperative cardiac troponin release and mortality in patients receiving volatile
      anesthetics when compared to patients receiving a TIVA. There are four published studies
      (Bignami et al. 2009) (De Hert et al. 2009) (Jackobsen et al. 2007) (Landoni et al. 2007)
      suggesting that these benefits can translate into a reduced mortality rate in patients
      receiving volatile agents. The level of evidence for these four studies is not high (one
      meta-regression, one underpowered randomized controlled study, one retrospective study and
      one meta-analysis of small randomized studies) and there is need for a large multicentre
      randomized controlled study to confirm these findings, as suggested by the international
      consensus conference on this topic published in 2011 (Landoni et al 2011).

      The purpose is to provide a large multicentre controlled randomized trial to demonstrate
      that volatile anesthetics can reduce 1 year mortality from 3% to 2% in patients undergoing
      CABG (either with or without cardiopulmonary bypass).

      The results of this study can support the use of volatile agents in all CABG procedures
      worldwide (more than 500.000 per year) with 2.500 lives saved per year (in the hypothesis
      that nowadays half the procedures are performed with a TIVA and that 1 year mortality can be
      reduced from 3% to 2% using volatile agents).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <condition>Aortocoronary Bypass</condition>
  <condition>Cardiac Surgery</condition>
  <condition>Coronary Artery Bypass Grafting</condition>
  <arm_group>
    <arm_group_label>volatile anesthetics (desflurane, isoflurane, sevoflurane)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>total intravenous anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desflurane, isoflurane, sevoflurane</intervention_name>
    <arm_group_label>volatile anesthetics (desflurane, isoflurane, sevoflurane)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>total intravenous anesthetics</intervention_name>
    <arm_group_label>total intravenous anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years

          -  written informed consent

          -  scheduled procedures

          -  planned isolated CABG (multiple bypass are allowed; planned combined intervention
             such as CABG plus valve surgery are not allowed

        Exclusion Criteria:

          -  pregnancy

          -  planned valve surgery or surgery on the aorta

          -  planned locoregional anesthesia without general anesthesia

          -  unstable or ongoing angina

          -  recent (&lt; 1 month) or ongoing acute myocardial infarction

          -  use of sulfonylurea, theophylline or allopurinol

          -  previous unusual response to an anesthetic agent

          -  inclusion in other randomised controlled studies in the previous 30 days

          -  any general anesthesia performed in the previous 30 days

          -  emergency operation (not scheduled)

          -  Kidney or liver transplant in medical history

          -  Liver cirrhosis (Child B or C)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>alberto zangrillo, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Vita-Salute University of Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>giovanni landoni, Prof</last_name>
    <email>landoni.giovanni@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Raffaele di Milano, Italy</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>giovanni landoni, prof</last_name>
      <email>landoni.giovanni@hsr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.unisr.it/persona.asp?id=8713&amp;linguacv=english</url>
    <description>CV Prof Landoni</description>
  </link>
  <reference>
    <citation>Landoni G, Greco T, Biondi-Zoccai G, Nigro Neto C, Febres D, Pintaudi M, Pasin L, Cabrini L, Finco G, Zangrillo A. Anaesthetic drugs and survival: a Bayesian network meta-analysis of randomized trials in cardiac surgery. Br J Anaesth. 2013 Dec;111(6):886-96. doi: 10.1093/bja/aet231. Epub 2013 Jul 12.</citation>
    <PMID>23852263</PMID>
  </reference>
  <reference>
    <citation>Landoni G, Rodseth RN, Santini F, Ponschab M, Ruggeri L, Székely A, Pasero D, Augoustides JG, Del Sarto PA, Krzych LJ, Corcione A, Slullitel A, Cabrini L, Le Manach Y, Almeida RM, Bignami E, Biondi-Zoccai G, Bove T, Caramelli F, Cariello C, Carpanese A, Clarizia L, Comis M, Conte M, Covello RD, De Santis V, Feltracco P, Giordano G, Pittarello D, Gottin L, Guarracino F, Morelli A, Musu M, Pala G, Pasin L, Pezzoli I, Paternoster G, Remedi R, Roasio A, Zucchetti M, Petrini F, Finco G, Ranieri M, Zangrillo A. Randomized evidence for reduction of perioperative mortality. J Cardiothorac Vasc Anesth. 2012 Oct;26(5):764-72. doi: 10.1053/j.jvca.2012.04.018. Epub 2012 Jun 20. Review.</citation>
    <PMID>22726656</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Vita-Salute San Raffaele</investigator_affiliation>
    <investigator_full_name>Giovanni Landoni</investigator_full_name>
    <investigator_title>MD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>volatile anesthetics</keyword>
  <keyword>desflurane</keyword>
  <keyword>isoflurane</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>TIVA</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>mortality</keyword>
  <keyword>anesthesia</keyword>
  <keyword>intensive care</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Anesthetics, Intravenous</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
